Welcome to our dedicated page for Horizon Therapeutics Plc news (Ticker: HZNP), a resource for investors and traders seeking the latest updates and insights on Horizon Therapeutics Plc stock.
Horizon Therapeutics plc (NASDAQ: HZNP) is a global biotechnology company dedicated to the discovery, development, and commercialization of medicines for rare, autoimmune, and severe inflammatory diseases. Horizon’s mission is to blend science and compassion to transform the lives of patients who are often underserved. The company’s therapeutic portfolio includes innovative products such as TEPEZZA® (teprotumumab-trbw) and KRYSTEXXA® (pegloticase injection), which address critical medical needs.
Horizon is driven by a deep understanding of the patient journey and aims to bring clinically meaningful therapies to those who need them most. The company is heavily invested in scientific research and development, and this commitment is evident in its robust pipeline of medicines designed to address complex medical conditions.
Recently, Horizon entered into a consent order agreement with the Federal Trade Commission (FTC) to resolve a pending administrative lawsuit, clearing the way for its acquisition by Amgen (NASDAQ: AMGN). This deal is expected to close in early fourth-quarter 2023, pending final approvals. Amgen, a pioneer in biotechnology, is committed to advancing human therapeutics and has been recognized as one of “America’s Greatest Workplaces” by Newsweek and one of “America’s Climate Leaders” by USA Today.
Horizon’s commitment to combining scientific expertise with compassionate care sets it apart in the biotech industry. By focusing on areas of high unmet medical need, Horizon aims to deliver breakthrough therapies that can improve health outcomes and dramatically enhance the quality of life for patients around the world.
For more information on Horizon and its groundbreaking work, visit its official website at HorizonTherapeutics.com and follow the company on social media platforms such as Twitter, LinkedIn, Instagram, and Facebook.
Horizon Therapeutics has announced results from the completed PROTECT trial, showing that KRYSTEXXA (pegloticase injection) effectively reduced serum uric acid in patients with uncontrolled gout post-kidney transplant, with 89% reaching the primary endpoint. At 24 weeks, pain and disability scores improved significantly. The trial involved 20 patients, with 18 included in the analysis. The company also highlighted the high prevalence of gout among dialysis patients, which poses serious health risks.
Horizon Therapeutics plc (Nasdaq: HZNP) announced the retirement of CFO Paul Hoelscher effective May 16, 2022, with Aaron Cox succeeding him. Hoelscher has been with Horizon since 2014, playing a crucial role in the company's growth. Cox, who joined Horizon in 2016, has led various strategic initiatives, including the Viela Bio acquisition. His extensive experience in corporate development and finance is expected to support Horizon's long-term strategy. Forward-looking statements regarding executive transitions and business growth were included, highlighting possible risks and uncertainties.
Horizon Therapeutics reported record third-quarter 2021 results with net sales of $1.037 billion, a 63% increase year-over-year. GAAP net income reached $326.5 million, and adjusted EBITDA was $509 million. Third-quarter net sales for TEPEZZA were $616.4 million, and for KRYSTEXXA, $158.1 million. The company raised its full-year 2021 net sales guidance to between $3.16 billion and $3.21 billion, representing approximately 45% growth at the midpoint. Horizon also announced five new R&D programs and positive results from the KRYSTEXXA MIRROR trial.
Horizon Therapeutics announces survey results indicating a negative stigma surrounding gout treatment among rheumatologists. The study, conducted with 106 practicing specialists, reveals that gout patients are perceived to have lower treatment compliance and worse outcomes than those with rheumatoid arthritis. Additionally, new analyses presented at the American College of Rheumatology Convergence 2021 highlight the benefits of using KRYSTEXXA (pegloticase injection) in conjunction with immunomodulation, achieving a 90% target serum uric acid level in patients. This evidence aims to improve clinical outcomes for uncontrolled gout patients.
Horizon Therapeutics plc (NASDAQ: HZNP) announced significant results from the MIRROR trial, demonstrating a 30 percentage point increase in response rates for chronic gout patients treated with KRYSTEXXA combined with methotrexate. Specifically, 71% of patients using this combination achieved treatment success compared to 40% for those receiving KRYSTEXXA with placebo (p<0.001). Horizon plans to file a Supplemental Biologics License Application (sBLA) with the FDA in Q1 2022, aiming to enhance treatment options for uncontrolled gout patients.
Horizon Therapeutics announced long-term efficacy results of TEPEZZA for Thyroid Eye Disease (TED) from the OPTIC-X trial, published in Ophthalmology. The trial indicated a 90.6% response rate for proptosis at Week 48 among patients previously treated with placebo. Additionally, 90% of OPTIC patients who completed the follow-up required no additional therapy. No new safety concerns were reported, supporting TEPEZZA's role in managing this serious autoimmune disease. This data enhances understanding of treatment longevity for TED patients.
Horizon Therapeutics plc (NASDAQ: HZNP) announced significant findings from the Phase 2/3 N-MOmentum trial of UPLIZNA, presented at ECTRIMS 2021. The analysis indicates a strong correlation between deep B-cell depletion and improved outcomes in patients with anti-aquaporin-4 antibody positive neuromyelitis optica spectrum disorder (NMOSD). UPLIZNA achieved a 97% reduction in annualized attack rates and a 73% decrease in new lesions compared to placebo. These results underscore the role of B cells in NMOSD and support UPLIZNA's efficacy in managing the condition.
Horizon Therapeutics plc (NASDAQ: HZNP) announced significant data presentations for TEPEZZA at the American Academy of Ophthalmology Annual Meeting from Nov. 12-15, 2021, in New Orleans. TEPEZZA is the first FDA-approved medication for Thyroid Eye Disease (TED), which poses serious risks to vision. Key presentations will cover real-world adherence to TEPEZZA and efficacy in TED patients with low inflammation. Horizon will also host a product theater discussing real-world cases in TED.
Horizon Therapeutics plc (Nasdaq: HZNP) is set to release its third-quarter 2021 financial results on November 3, 2021, at 8 a.m. Eastern Time. Following this, a live webcast will be available for management to discuss the financial and operational outcomes. Investors can access the webcast via Horizon's investor relations website. Horizon focuses on developing treatments for rare, autoimmune, and severe inflammatory diseases, emphasizing the integration of science and compassion to profoundly impact patients' lives.
FAQ
What is Horizon Therapeutics?
What products does Horizon Therapeutics offer?
What recent achievements has Horizon Therapeutics made?
Who is acquiring Horizon Therapeutics?
How is Horizon Therapeutics contributing to medical science?
What is the mission of Horizon Therapeutics?
How can I learn more about Horizon Therapeutics?
What is the significance of Horizon’s recent agreement with the FTC?
Where is Horizon Therapeutics headquartered?
What is the focus of Horizon's research and development efforts?
